Can an Oxygen-Boosting drug help when all else fails?

NCT ID NCT07748299

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This program allows doctors to request NanO₂, an investigational drug that may help deliver oxygen to tissues, for patients with serious or life-threatening conditions like glioblastoma, respiratory distress, or ischemic stroke. It is for patients who have exhausted other treatments and cannot join a clinical trial. Each request is reviewed individually, and the drug is not FDA-approved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NanO₂ (NVX-108), an investigational oxygen-carrying drug
What this could lead to
If successful, this expanded access program could provide a potential treatment option for patients with life-threatening conditions who have no other choices.
What could go wrong
This is an early-stage, unapproved drug with unknown risks and benefits. Access is not guaranteed, and it may not work for every patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.